Catalyst Q2 revenue $122.7M (+23% YoY); GAAP EPS $0.33, non-GAAP $0.56; guides upper end of $455-475M

CATALYST PHARMACEUTICALS, INC.

2024-Q2 EPS reported $0.52 revenue$221,219,000

Total Q2 2024 revenue $122.7M, up 23.3% YoY; FIRDAPSE $77.4M (+19.2%), FYCOMPA $36.5M (+5.7%), AGAMREE $8.7M (new launch).
GAAP net income $40.8M ($0.33 diluted); non-GAAP net income $69.6M ($0.56 diluted), up 15.3% YoY.
Cash and equivalents $375.7M at June 30, 2024, up from $137.6M at Dec 31, 2023 (+173%).
Reaffirms 2024 total revenue guidance of $455-$475M; expects results in upper half of range.
Announced license agreement for AGAMREE in Canada to expand rare orphan portfolio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.